Published in Mol Cancer Res on October 01, 2003
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Human MicroRNA targets. PLoS Biol (2004) 34.51
Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res (2005) 29.17
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol (2009) 19.99
Identification of mammalian microRNA host genes and transcription units. Genome Res (2004) 14.63
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A (2004) 14.59
An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci U S A (2004) 13.66
Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A (2005) 12.96
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 12.26
The colorectal microRNAome. Proc Natl Acad Sci U S A (2006) 11.59
A combined computational-experimental approach predicts human microRNA targets. Genes Dev (2004) 9.82
Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res (2005) 9.80
The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A (2005) 8.60
Modulation of microRNA processing by p53. Nature (2009) 7.88
Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA (2004) 7.71
MicroRNA expression detected by oligonucleotide microarrays: system establishment and expression profiling in human tissues. Genome Res (2004) 6.98
Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer (2007) 6.57
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol (2007) 6.41
Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer (2006) 6.39
miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A (2008) 6.24
Inference of miRNA targets using evolutionary conservation and pathway analysis. BMC Bioinformatics (2007) 6.21
MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol (2011) 5.46
MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer (2006) 5.37
A high-throughput method to monitor the expression of microRNA precursors. Nucleic Acids Res (2004) 5.21
MicroRNAs in cancer. Annu Rev Pathol (2009) 4.47
Real-time PCR quantification of precursor and mature microRNA. Methods (2008) 4.12
MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci U S A (2008) 4.06
Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors. RNA (2007) 3.91
Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol (2006) 3.71
Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res (2008) 3.67
The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ (2009) 3.43
Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum (2008) 3.35
MicroRNAs: regulators of gene expression and cell differentiation. Blood (2006) 3.08
RNAdb--a comprehensive mammalian noncoding RNA database. Nucleic Acids Res (2005) 2.84
Tissue-dependent paired expression of miRNAs. Nucleic Acids Res (2007) 2.82
Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm Genome (2006) 2.64
MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One (2008) 2.60
MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer (2009) 2.57
Human microRNA prediction through a probabilistic co-learning model of sequence and structure. Nucleic Acids Res (2005) 2.48
MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer (2009) 2.45
MicroRNA and cancer--focus on apoptosis. J Cell Mol Med (2009) 2.44
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev (2009) 2.41
Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev (2010) 2.37
MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer (2010) 2.33
Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer (2009) 2.27
Regulation of MicroRNA Biogenesis: A miRiad of mechanisms. Cell Commun Signal (2009) 2.27
Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS One (2008) 2.27
Retracted Differential expression of microRNAs in myometrium and leiomyomas and regulation by ovarian steroids. J Cell Mol Med (2007) 2.24
Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS One (2009) 2.21
Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst (2008) 2.20
Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res (2009) 2.19
MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer. BMC Cancer (2010) 2.10
Proinflammatory role for let-7 microRNAS in experimental asthma. J Biol Chem (2010) 2.08
Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci (2013) 2.00
Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. Cancer Genomics Proteomics (2006) 1.94
Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol Cell (2010) 1.92
MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines. Cancer Lett (2009) 1.92
Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist (2010) 1.91
MicroRNA let-7: an emerging next-generation cancer therapeutic. Curr Oncol (2010) 1.90
Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol (2007) 1.90
MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics (2009) 1.88
MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br J Cancer (2009) 1.88
miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS One (2009) 1.84
MicroRNAs in tumorigenesis: a primer. Am J Pathol (2007) 1.83
miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ (2009) 1.82
Identification of the human mature B cell miRNome. Immunity (2009) 1.82
Ultra-high throughput sequencing-based small RNA discovery and discrete statistical biomarker analysis in a collection of cervical tumours and matched controls. BMC Biol (2010) 1.80
Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One (2012) 1.80
down-regulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphogenetic protein 4. J Biol Chem (2011) 1.79
MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther (2011) 1.77
MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res (2011) 1.77
MicroRNAs in gene regulation: when the smallest governs it all. J Biomed Biotechnol (2006) 1.76
Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther (2011) 1.76
MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer (2010) 1.74
MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One (2009) 1.73
Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol (2013) 1.73
Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. Br J Cancer (2011) 1.73
Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. J Clin Invest (2007) 1.72
miRNA expression in colon polyps provides evidence for a multihit model of colon cancer. PLoS One (2011) 1.72
Global changes in processing of mRNA 3' untranslated regions characterize clinically distinct cancer subtypes. Cancer Res (2009) 1.70
MicroRNA profiling and head and neck cancer. Comp Funct Genomics (2009) 1.68
miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res (2010) 1.67
MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer (2010) 1.66
MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro. J Cell Biol (2010) 1.64
MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One (2010) 1.64
Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotrophic virus 1. Cancer Res (2008) 1.63
miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J Biol Chem (2011) 1.63
Epigenetics of colorectal cancer. Gastroenterology (2012) 1.60
Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome. Am J Hum Genet (2008) 1.59
Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing. PLoS One (2012) 1.58
Myc: Maestro of MicroRNAs. Genes Cancer (2010) 1.58
MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer Res (2011) 1.57
MicroRNAs, macrocontrol: regulation of miRNA processing. RNA (2010) 1.56
MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. Cancer Genomics Proteomics (2009) 1.55
The role of microRNAs in cancer. Yale J Biol Med (2006) 1.54
Epigenetic modifications in cancer. Clin Genet (2011) 1.53
MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtype. Genes Chromosomes Cancer (2010) 1.51
Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer (2006) 2.47
Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst (2012) 2.44
Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut (2010) 2.30
Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol (2012) 2.22
A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst (2012) 1.83
Interval fecal immunochemical testing in a colonoscopic surveillance program speeds detection of colorectal neoplasia. Gastroenterology (2010) 1.74
Shift to earlier stage at diagnosis as a consequence of the National Bowel Cancer Screening Program. Med J Aust (2013) 1.73
Applying evidence-based guidelines improves use of colonoscopy resources in patients with a moderate risk of colorectal neoplasia. Med J Aust (2002) 1.73
Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat (2013) 1.55
Evaluation of oral rehydration solution by whole-gut perfusion in rats: effect of osmolarity, sodium concentration and resistant starch. J Pediatr Gastroenterol Nutr (2006) 1.41
Mannose-binding lectin deficiency does not increase the prevalence of Helicobacter pylori seropositivity. Eur J Gastroenterol Hepatol (2007) 1.38
Colorectal Neoplasia Differentially Expressed (CRNDE), a Novel Gene with Elevated Expression in Colorectal Adenomas and Adenocarcinomas. Genes Cancer (2011) 1.28
Phenotypic diversity in patients with multiple serrated polyps: a genetics clinic study. Int J Colorectal Dis (2010) 1.27
A panel of genes methylated with high frequency in colorectal cancer. BMC Cancer (2014) 1.26
Protocol for population testing of an Internet-based Personalised Decision Support system for colorectal cancer screening. BMC Med Inform Decis Mak (2010) 1.24
Psychosocial variables associated with colorectal cancer screening in South Australia. Int J Behav Med (2011) 1.17
Human gastrointestinal neoplasia-associated myofibroblasts can develop from bone marrow-derived cells following allogeneic stem cell transplantation. Stem Cells (2009) 1.14
Effect of high amylose maize starches on colonic fermentation and apoptotic response to DNA-damage in the colon of rats. Nutr Metab (Lond) (2009) 1.13
Map of differential transcript expression in the normal human large intestine. Physiol Genomics (2007) 1.11
A synbiotic combination of resistant starch and Bifidobacterium lactis facilitates apoptotic deletion of carcinogen-damaged cells in rat colon. J Nutr (2005) 1.05
Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers. Ann Surg Oncol (2013) 1.03
Behavioural and demographic predictors of adherence to three consecutive faecal occult blood test screening opportunities: a population study. BMC Public Health (2014) 1.01
Effect of dietary resistant starch and protein on colonic fermentation and intestinal tumourigenesis in rats. Carcinogenesis (2006) 1.00
Predictors of re-participation in faecal occult blood test- based screening for colorectal cancer. Asian Pac J Cancer Prev (2012) 0.97
Evaluation of an automated immunochemical fecal occult blood test for colorectal neoplasia detection in a Chinese population. Cancer (2003) 0.97
Amylase-resistant starch as adjunct to oral rehydration therapy in children with diarrhea. J Pediatr Gastroenterol Nutr (2006) 0.96
Comparing fecal immunochemical tests: improved standardization is needed. Gastroenterology (2012) 0.95
Effect of resistant starch on genotoxin-induced apoptosis, colonic epithelium, and lumenal contents in rats. Carcinogenesis (2003) 0.94
Synbiotic intervention of Bifidobacterium lactis and resistant starch protects against colorectal cancer development in rats. Carcinogenesis (2009) 0.93
Colorectal cancer linkage on chromosomes 4q21, 8q13, 12q24, and 15q22. PLoS One (2012) 0.93
Absence of acute apoptotic response to genotoxic carcinogens in p53-deficient mice is associated with increased susceptibility to azoxymethane-induced colon tumours. Int J Cancer (2005) 0.93
Are the common genetic variants associated with colorectal cancer risk for DNA mismatch repair gene mutation carriers? Eur J Cancer (2013) 0.92
Suppression of azoxymethane-induced colon cancer development in rats by dietary resistant starch. Cancer Biol Ther (2007) 0.89
Discovery and validation of molecular biomarkers for colorectal adenomas and cancer with application to blood testing. PLoS One (2012) 0.89
Suppression of colorectal oncogenesis by selenium-enriched milk proteins: apoptosis and K-ras mutations. Cancer Res (2008) 0.88
Effects of high-amylose maize starch and butyrylated high-amylose maize starch on azoxymethane-induced intestinal cancer in rats. Carcinogenesis (2008) 0.88
Analysis of families with Lynch syndrome complicated by advanced serrated neoplasia: the importance of pathology review and pedigree analysis. Fam Cancer (2009) 0.87
Inhibition by resistant starch of red meat-induced promutagenic adducts in mouse colon. Cancer Prev Res (Phila) (2011) 0.86
Sulindac corrects defective apoptosis and suppresses azoxymethane-induced colonic oncogenesis in p53 knockout mice. Int J Cancer (2005) 0.84
Demographic associations with stage of readiness to screen for colorectal cancer. Health Promot J Austr (2009) 0.84
A human, double-blind, placebo-controlled, crossover trial of prebiotic, probiotic, and synbiotic supplementation: effects on luminal, inflammatory, epigenetic, and epithelial biomarkers of colorectal cancer. Am J Clin Nutr (2009) 0.84
Improving the reporting of evaluations of faecal immunochemical tests for haemoglobin: the FITTER standard and checklist. Eur J Cancer Prev (2015) 0.84
Using the Transtheoretical Model of Behaviour Change to describe readiness to rescreen for colorectal cancer with faecal occult blood testing. Health Promot J Austr (2012) 0.83
Dietary red meat aggravates dextran sulfate sodium-induced colitis in mice whereas resistant starch attenuates inflammation. Dig Dis Sci (2013) 0.83
Making colorectal cancer screening FITTER for purpose with quantitative faecal immunochemical tests for haemoglobin (FIT). Clin Chem Lab Med (2013) 0.83
The urgency of saving lives through bowel cancer screening. Med J Aust (2012) 0.83
Butyrate delivered by butyrylated starch increases distal colonic epithelial apoptosis in carcinogen-treated rats. Carcinogenesis (2011) 0.83
Repair and removal of azoxymethane-induced O6-methylguanine in rat colon by O6-methylguanine DNA methyltransferase and apoptosis. Mutat Res (2013) 0.83
Evidence of linkage to chromosomes 10p15.3-p15.1, 14q24.3-q31.1 and 9q33.3-q34.3 in non-syndromic colorectal cancer families. Eur J Hum Genet (2011) 0.82
Quantitation of hemoglobin improves fecal immunochemical tests for noninvasive screening. Clin Gastroenterol Hepatol (2013) 0.82
Selenium-rich foods: a promising approach to colorectal cancer prevention. Curr Pharm Biotechnol (2012) 0.82
Detection of K-ras mutations in azoxymethane-induced aberrant crypt foci in mice using LNA-mediated real-time PCR clamping and mutant-specific probes. Mutat Res (2009) 0.82
Ambivalence and its influence on participation in screening for colorectal cancer. Qual Health Res (2013) 0.82
Colorectal cancer screening in rural and remote areas: analysis of the National Bowel Cancer Screening Program data for South Australia. Rural Remote Health (2011) 0.81
DNA methylation in the rectal mucosa is associated with crypt proliferation and fecal short-chain fatty acids. Dig Dis Sci (2010) 0.81
A randomized controlled trial of glucose versus amylase resistant starch hypo-osmolar oral rehydration solution for adult acute dehydrating diarrhea. PLoS One (2008) 0.81
Accumulation of promutagenic DNA adducts in the mouse distal colon after consumption of heme does not induce colonic neoplasms in the western diet model of spontaneous colorectal cancer. Mol Nutr Food Res (2013) 0.81
Combination of selenium and green tea improves the efficacy of chemoprevention in a rat colorectal cancer model by modulating genetic and epigenetic biomarkers. PLoS One (2013) 0.81
Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer. Eur J Gastroenterol Hepatol (2006) 0.81
Rising incidence of early-onset colorectal cancer in Australia over two decades: report and review. J Gastroenterol Hepatol (2015) 0.81
Selenium-enriched milk proteins and selenium yeast affect selenoprotein activity and expression differently in mouse colon. Br J Nutr (2010) 0.80
Improving Participation in Colorectal Cancer Screening: a Randomised Controlled Trial of Sequential Offers of Faecal then Blood Based Non-Invasive Tests. Asian Pac J Cancer Prev (2015) 0.80
Sensitive and selective amplification of methylated DNA sequences using helper-dependent chain reaction in combination with a methylation-dependent restriction enzymes. Nucleic Acids Res (2012) 0.79
Fermentation of starch and protein in the colon: implications for genomic instability. Cancer Biol Ther (2007) 0.79
Fecal Tests: From Blood to Molecular Markers. Curr Colorectal Cancer Rep (2011) 0.79
The influence of selenium-enriched milk proteins and selenium yeast on plasma selenium levels and rectal selenoprotein gene expression in human subjects. Br J Nutr (2011) 0.79
Oral rehydration therapy in the second decade of the twenty-first century. Curr Gastroenterol Rep (2014) 0.78
The potential of sphingomyelin as a chemopreventive agent in AOM-induced colon cancer model: wild-type and p53+/- mice. Mol Nutr Food Res (2008) 0.78
Anti-mutagenic lichen extract has double-edged effect on azoxymethane-induced colorectal oncogenesis in C57BL/6J mice. Toxicol Mech Methods (2010) 0.78
R-flurbiprofen suppresses distal nonmucin-producing colorectal tumors in azoxymethane-treated rats, without suppressing eicosanoid production. Am J Physiol Gastrointest Liver Physiol (2010) 0.78
Newer fecal tests: opportunities for professionals in laboratory medicine. Clin Chem (2012) 0.77
Defective acute apoptotic response to genotoxic carcinogen in small intestine of APC(Min/+) mice is restored by sulindac. Cancer Lett (2006) 0.77
Treatment patterns among colorectal cancer patients in South Australia: a demonstration of the utility of population-based data linkage. J Eval Clin Pract (2014) 0.77
Participant satisfaction with fecal occult blood test screening for colorectal cancer. J Gastroenterol Hepatol (2007) 0.77
A standard for Faecal Immunochemical TesTs for haemoglobin evaluation reporting (FITTER). Ann Clin Biochem (2013) 0.77
Comparing the effects of COX and non-COX-inhibiting NSAIDs on enhancement of apoptosis and inhibition of aberrant crypt foci formation in a rat colorectal cancer model. Anticancer Res (2013) 0.77
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med (2009) 0.76
Exploring the validity of the continuum of resistance model for discriminating early from late and non-uptake of colorectal cancer screening: implications for the design of invitation and reminder letters. Int J Behav Med (2013) 0.76
Role of Red Meat and Resistant Starch in Promutagenic Adduct Formation, MGMT Repair, Thymic Lymphoma and Intestinal Tumourigenesis in Msh2 -Deficient Mice. J Nutrigenet Nutrigenomics (2015) 0.76
Fecal DNA for colorectal-cancer screening. N Engl J Med (2005) 0.75
Little evidence for association between the TGFBR1*6A variant and colorectal cancer: a family-based association study on non-syndromic family members from Australia and Spain. BMC Cancer (2014) 0.75
Screening with a fecal multitarget DNA test. Gastroenterology (2005) 0.75
Inhibition of oxidative stress and apoptosis enables extended maintenance of integrity and function of isolated hepatocytes in suspension. J Gastroenterol Hepatol (2009) 0.75
Patient and carer perceptions of cancer care in South Australia. Aust Health Rev (2009) 0.75
Uptake of a colorectal cancer screening blood test in people with elevated risk for cancer who cannot or will not complete a faecal occult blood test. Eur J Cancer Prev (2017) 0.75